Cor Vasa 2022, 64(1):34-37 | DOI: 10.33678/cor.2021.086

Adipsin as a novel prognostic biomarker for cardiovascular diseases

Lutfu Askina, Husna Sengul Askinb, Sabri Abusc, Siho Hidayetd
a Department of Cardiology, Adiyaman Education and Research Hospital, Adiyaman, Turkey
b Department of Infectious Diseases, Adiyaman Education and Research Hospital, Adiyaman, Turkey
c Department of Cardiology, Kahta State Hospital, Adiyaman, Turkey
d Department of Cardiology, Inonu University Medicine Faculty, Malatya, Turkey

Increased vascular oxidative stress stimulates the secretion of adipokines from adipocytes. Many clinical studies have demonstrated that plasma adipsin levels are successful in predicting ischemic events. Increased adipsin levels are closely related to all-cause death and morbidity. Therefore, adipsin may be a new biomarker for atherosclerosis. In this review, we aimed to emphasize the association of adipsin with cardiovascular diseases (CVDs) and its beneficial role in the therapeutic field of CVDs.

Keywords: Adipsin, Atherosclerosis, Cardiovascular disease

Received: May 29, 2021; Revised: July 1, 2021; Accepted: July 10, 2021; Published: February 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Askin L, Askin HS, Abus S, Hidayet S. Adipsin as a novel prognostic biomarker for cardiovascular diseases. Cor Vasa. 2022;64(1):34-37. doi: 10.33678/cor.2021.086.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nguyen HN, Fujiyoshi A, Abbott RD, et al. Epidemiology of cardiovascular risk factors in Asian countries. Circ J 2013;77:2851-2859. Go to original source... Go to PubMed...
    2. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-952. Go to original source... Go to PubMed...
    3. Chiuve SE, McCullough ML, Sacks FM, et al. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: Benefits among users and nonusers of lipid- -lowering and antihypertensive medications. Circulation 2006;114:160-167. Go to original source... Go to PubMed...
    4. Aşkin L, Karakelleoğlu Ş, Değirmenci H, et al. Comparison of the effects of metoprolol or carvedilol on serum gamma- -glutamyltransferase and uric acid levels among patients with acute coronary syndrome without ST segment elevation. Anatol J Cardiol 2016;16:16-22. Go to original source... Go to PubMed...
    5. Casale M, Mezzetti M, Tulino V, et al. Therapy Of Cardiac Arrhythmias In Children: An Emerging Role Of Electroanatomical Mapping Systems. Curr Vasc Pharmacol 2018;16:528-533. Go to original source... Go to PubMed...
    6. Spencer FA, Meyer TE, Gore JM, et al. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction. Circulation 2002;105:2605-2610. Go to original source... Go to PubMed...
    7. Casale M, Correale M, Laterra G, et al. Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and an ICD: A Longitudinal Study. Clin Drug Investig 2021;41:169-176. Go to original source... Go to PubMed...
    8. Casale M, Mezzetti M, Gigliotti De Fazio M, et al. Usefulness of Sacubitril/Valsartan in reduction of atrial fibrillation burden in a patient with ICD delivering inappropriate therapies. A new possibility? Cor Vasa 2020;62:336-339. Go to original source...
    9. Casale M, Quattrocchi S, Bitto R, et al. Cardiac implantable devices and takotsubo syndrome. A rare but potential eventuality. Cor Vasa 2018;60:e500-e502. Go to original source...
    10. Mähönen M, Salomaa V, Brommels M, et al. The validity of hospital discharge register data on coronary heart disease in Finland. Eur J Epidemiol 1997;13:403-415. Go to original source... Go to PubMed...
    11. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003;41:37S-42S. Go to original source... Go to PubMed...
    12. Satoh K. AMPKa2 regulates hypoxia-inducible factor-1a stability and neutrophil survival to promote vascular repair after ischemia. Circ Res 2017;120:8-10. Go to original source... Go to PubMed...
    13. Satoh K, Satoh T, Kikuchi N, et al. Basigin mediates pulmonary hypertension by promoting inflammation and vascular smooth muscle cell proliferation. Circ Res 2014;115:738-750. Go to original source... Go to PubMed...
    14. Shimokawa H. 2014 Williams Harvey Lecture: importance of coronary vasomotion abnormalities - from bench to bedside. Eur Heart J 2014;35:3180-3193. Go to original source... Go to PubMed...
    15. Satoh K, Matoba T, Suzuki J, et al. Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation 2008;117:3088-3098. Go to original source... Go to PubMed...
    16. Satoh K, Kikuchi N, Kurosawa R, et al. PDE1C negatively regulates growth factor receptor degradation and promotes VSMC proliferation. Circ Res 2015;116:1098-1100. Go to original source... Go to PubMed...
    17. Shimokawa H, Sunamura S, Satoh K. RhoA/Rho-kinase in the cardiovascular system. Circ Res 2016;118:352-366. Go to original source... Go to PubMed...
    18. Satoh K, Nigro P, Matoba T, et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med 2009;15:649-656. Go to original source... Go to PubMed...
    19. Satoh K, Shimokawa H. High-sensitivity C-reactive protein: still need for nextgeneration biomarkers for remote future cardiovascular events. Eur Heart J 2014;35:1776-1778. Go to original source... Go to PubMed...
    20. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008;8:776-787. Go to original source... Go to PubMed...
    21. Satoh T, Satoh K, Yaoita N, et al. Activated TAFI promotes the development of chronic thromboembolic pulmonary hypertension: a possible novel therapeutic target. Circ Res 2017;120:1246-1262. Go to original source... Go to PubMed...
    22. Lo JC, Ljubicic S, Leibiger B, et al. Adipsin is an adipokine that improves b cell function in diabetes. Cell 2014;158:41-53. Go to original source... Go to PubMed...
    23. Luc G, Empana JP, Morange P, et al. Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study. Int J Obes (Lond) 2010;34:118-126. Go to original source... Go to PubMed...
    24. Prugger C, Luc G, Haas B, et al. Adipocytokines and the risk of ischemic stroke: the PRIME Study. Ann Neurol 2012;71:478-486. Go to original source... Go to PubMed...
    25. Vasilenko MA, Kirienkova EV, Skuratovskaia DA, et al. The role of production of adipsin and leptin in the development of insulin resistance in patients with abdominal obesity. Dokl Biochem Biophys 2017;475:271-276. Go to original source... Go to PubMed...
    26. Tafere GG, Wondafrash DZ, Zewdie KA, et al. Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes 2020;13:1855-1861. Go to original source... Go to PubMed...
    27. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003;100:7265-7270. Go to original source... Go to PubMed...
    28. Nasu K, Tsuchikane E, Katoh O, et al. Plaque characterisation by virtual histology intravascular ultrasound analysis in patients with type 2 diabetes. Heart 2008;94:429-433. Go to original source... Go to PubMed...
    29. Gursoy CO, Calan M, Yesil SP, et al. Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2016;85:910-917. Go to original source... Go to PubMed...
    30. Song NJ, Kim S, Jang BH, et al. Small molecule-induced complement factor D (adipsin) promotes lipid accumulation and adipocyte differentiation. PLoS One 2016;11:e0162228. Go to original source... Go to PubMed...
    31. Ohtsuki T, Satoh K, Shimizu T, et al. Identification of Adipsinas a Novel Prognostic Biomarker in Patients With Coronary Artery Disease. J Am Heart Assoc 2019;8:e013716. Go to original source... Go to PubMed...
    32. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-663. Go to original source... Go to PubMed...
    33. Fujimoto H, Suzuki T, Aizawa K, et al. Processed B-type natriuretic peptide is a biomarker of postinterventional restenosis in ischemic heart disease. Clin Chem 2013;59:1330-1337. Go to original source... Go to PubMed...
    34. Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 2004;148:S19-S26. Go to original source... Go to PubMed...
    35. Martinez HR, Escamilla-Ocanas CE, Camara-Lemarroy CR, et al. CSF concentrations of adipsin and adiponectin in patients with amyotrophic lateral sclerosis. Acta Neurol Belg 2017;117:879-883. Go to original source... Go to PubMed...
    36. Natarajan R, Hagman S, Hamalainen M, et al. Adipsin is associated with multiple sclerosis: a follow-up study of adipokines. Mult Scler Int 2015;2015:371734. Go to original source... Go to PubMed...
    37. Gómez-Banoy N, Guseh JS, Li G, et al. Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans. Nat Med 2019;25:1739-1747. Go to original source... Go to PubMed...
    38. Wang Y, Zheng X, Xie X, et al. Correlation of increased serum adipsin with increased cardiovascular risks in adult patients with growth hormone deficiency. Endocr Pract 2019;25:446-453. Go to original source... Go to PubMed...
    39. Brady SRE, Mousa A, Naderpoor N, et al. Adipsin Concentrations Are Associated with Back Pain Independently of Adiposity in Overweight or Obese Adults. Front Physiol 2018;9:93. Go to original source... Go to PubMed...
    40. Korman BD, Marangoni RG, Hinchcliff M, et al. Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis Rheumatol 2017;69:2062-2068. Go to original source... Go to PubMed...
    41. Chedraui P, Pérez-López FR, Escobar GS, et al. Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome. Maturitas 2014;79:86-90. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes